Integrated Allergy and Asthma Prevention and Care: Report of the MeDALL/AIRWAYS ICPs Meeting at the Ministry of Health and Care Services, Oslo, Norway

Carlsen, Karin C. Lødrup; Haahtela, Tari; Smith, Anders; Bjerke, Marianne; Wickman, Magnus; Keil, Thomas; Ballereau, Stéphane; Bedbrook, Anna; Bergstroem, Anna; Nawjin, Martijn C.; Pinart, Mariona; Skrindo, I.; Xu, Cheng‐Jian; Carlo, Giuseppe De; Antó, Josep M.; Bousquet, Jean

doi:10.1159/000431359

Cited by 15 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measuring the temporal trend of asthma and allergic diseases is also important to understanding the epidemiology of these diseases. Furthermore, the data of asthma and allergic disease prevalence is an important guide in forming health policies [20]. When compared to the previous decade, physician-diagnosed asthma and rhinitis prevalence in our region has shown a nearly 2-fold increase in the last 10 years.…”

Section: Discussionmentioning

confidence: 99%

The Trend of Change of Allergic Diseases over the Years: Three Repeated Surveys from 1994 to 2014

Doğruel¹,

Bingöl²,

Altıntaş³

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Although it is known that there has been an increase in asthma and allergic diseases among school-aged children, results vary between countries. The aim of this study was to examine trends in the prevalence of these diseases in the city of Adana (south Turkey) over the last 20 years based on the results of 3 cross-sectional studies. Methods: Three cross-sectional surveys were performed 10 years apart in south Turkey. Here, we compare the surveys conducted among children between the ages of 6 and 14 years from 1994, 2004, and 2014. The participants were randomly chosen among children attending participating primary schools in Adana. The questionnaire in the first survey contained almost the same questions as the ISAAC. In the 2 latter surveys, we used the ISAAC questionnaire to investigate the prevalence of asthma and other allergic diseases. Results: A total of 2,334 children in 1994, 3,728 children in 2004, and 3,209 children in 2014 were included in the final analysis. The results showed a statistically significant increase in the prevalence of physician-diagnosed allergic diseases across the years, respectively: asthma (5, 4.6, and 8.9%), allergic rhinitis (8.8, 11.4, and 15.6%), and atopic dermatitis (5, 9.9, and 7%). In contrast, the prevalence of parent-reported current wheeze (16.2, 13.2%) decreased in the last 10 years. Conclusions: Our findings were consistent with the increased prevalence of childhood asthma and other allergic diseases. However, this pattern did not occur in respiratory symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

The Trend of Change of Allergic Diseases over the Years: Three Repeated Surveys from 1994 to 2014

Doğruel¹,

Bingöl²,

Altıntaş³

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The first results of ‘The Finnish Allergy Programme 2008–2018’ , supported by MeDALL data, indicate that allergy burden can be reduced with relatively simple means. This has been endorsed by the Norwegian Allergy Health Programme and, along with the Finnish programme, will serve as a platform for other countries (Oslo, November 2014) .…”

Section: Medall At the Cross‐roads Of The Eu And Who Political Agendamentioning

confidence: 99%

Paving the way of systems biology and precision medicine in allergic diseases: the Me DALL success story

Bousquet

Antó

Akdiş

et al. 2016

Allergy

View full text Add to dashboard Cite

MeDALL (Mechanisms of the Development of ALLergy; EU FP7‐CP‐IP; Project No: 261357; 2010–2015) has proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epidemiological, clinical and basic research using a stepwise, large‐scale and integrative approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology (omics, IgE measurement using microarrays) and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitization. IgE sensitization should be considered differently in monosensitized and polysensitized individuals. Allergic multimorbidities and IgE polysensitization are often associated with the persistence or severity of allergic diseases. Environmental exposures are relevant for the development of allergy‐related diseases. To complement the population‐based studies in children, MeDALL included mechanistic experimental animal studies and in vitro studies in humans. The integration of multimorbidities and polysensitization has resulted in a new classification framework of allergic diseases that could help to improve the understanding of genetic and epigenetic mechanisms of allergy as well as to better manage allergic diseases. Ethics and gender were considered. MeDALL has deployed translational activities within the EU agenda.

show abstract

“…Emilia-Romagna) are involved in AIRWAYS ICPs. One of the commitments for action (Norway) is a joint action between the Ministry of Health of Finland and Norway [ 43 ].…”

Section: Application Of the Eip On Aha Scaling Up Strategy To Chronicmentioning

confidence: 99%

“…The Collaborative Network decided to include AIRWAYS ICPs in its priorities for scaling up and implementation (M Bewick, R Pengelly, Secretary of State of Northern Ireland) [ 28 , 29 ] 05-11 Salzburg (Austria) Annual meeting of the Austrian Allergy Society 07-11 Guangzhou (China) Annual meeting: Discussion for the deployment of AIRWAYS ICPs and MACVIA–ARIA in China (NS Zhong, former President of the Chinese Medical Association) [ 88 ] 20-11 Oslo (Norway) Commitments for Action Oslo, Helsinki and Montpellier (K Lodrup Carlsen, T Haahtela, JB). The agreement for the deployment of the Finnish Allergy Programme in Norway was discussed at the Ministry of Health [ 43 ] Network of excellence centres in respiratory and allergic diseases : It includes the Commitments for Action (EIP on AHA action Plan B3), Reference Sites of the EIP AHA, the Global Allergy and Asthma European Network (GA 2 LEN) and members of AIRWAYS ICPs. GA 2 LEN, a Sixth European Union Framework Programme for Research and Technological Development (FP6) Network of Excellence, was created in 2005 as a vehicle to ensure excellence in research bringing together research and clinical institutions to combat fragmentation in the European research area and to tackle allergy in its globality [ 89 ].…”

Section: Application Of the Eip On Aha Scaling Up Strategy To Chronicmentioning

confidence: 99%

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Bousquet

Farrell

Crooks³

et al. 2016

Clin Transl Allergy

View full text Add to dashboard Cite

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing. Electronic supplementary materialThe online version of this article (doi:10.1186/s13601-016-0116-9) contains supplementary material, which is available to authorized users.

show abstract

Integrated Allergy and Asthma Prevention and Care: Report of the MeDALL/AIRWAYS ICPs Meeting at the Ministry of Health and Care Services, Oslo, Norway

Cited by 15 publications

References 28 publications

The Trend of Change of Allergic Diseases over the Years: Three Repeated Surveys from 1994 to 2014

The Trend of Change of Allergic Diseases over the Years: Three Repeated Surveys from 1994 to 2014

Paving the way of systems biology and precision medicine in allergic diseases: the Me DALL success story

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Contact Info

Product

Resources

About